127 related articles for article (PubMed ID: 22954307)
1. Gold nanoparticles as an HIV entry inhibitor.
Vijayakumar S; Ganesan S
Curr HIV Res; 2012 Dec; 10(8):643-6. PubMed ID: 22954307
[TBL] [Abstract][Full Text] [Related]
2. Glycoside analogs of beta-galactosylceramide, a novel class of small molecule antiviral agents that inhibit HIV-1 entry.
Garg H; Francella N; Tony KA; Augustine LA; Barchi JJ; Fantini J; Puri A; Mootoo DR; Blumenthal R
Antiviral Res; 2008 Oct; 80(1):54-61. PubMed ID: 18538869
[TBL] [Abstract][Full Text] [Related]
3. Closing two doors of viral entry: intramolecular combination of a coreceptor- and fusion inhibitor of HIV-1.
Kopetzki E; Jekle A; Ji C; Rao E; Zhang J; Fischer S; Cammack N; Sankuratri S; Heilek G
Virol J; 2008 May; 5():56. PubMed ID: 18452606
[TBL] [Abstract][Full Text] [Related]
4. HIV-1 Entry and Membrane Fusion Inhibitors.
Xiao T; Cai Y; Chen B
Viruses; 2021 Apr; 13(5):. PubMed ID: 33922579
[TBL] [Abstract][Full Text] [Related]
5. Gold manno-glyconanoparticles for intervening in HIV gp120 carbohydrate-mediated processes.
Di Gianvincenzo P; Chiodo F; Marradi M; Penadés S
Methods Enzymol; 2012; 509():21-40. PubMed ID: 22568899
[TBL] [Abstract][Full Text] [Related]
6. High-Throughput HIV-Cell Fusion Assay for Discovery of Virus Entry Inhibitors.
Marin M; Du Y; Giroud C; Kim JH; Qui M; Fu H; Melikyan GB
Assay Drug Dev Technol; 2015 Apr; 13(3):155-66. PubMed ID: 25871547
[TBL] [Abstract][Full Text] [Related]
7. A novel small-molecule inhibitor of HIV-1 entry.
Heredia A; Latinovic OS; Barbault F; de Leeuw EP
Drug Des Devel Ther; 2015; 9():5469-78. PubMed ID: 26491257
[TBL] [Abstract][Full Text] [Related]
8. Is there a future for antiviral fusion inhibitors?
Berkhout B; Eggink D; Sanders RW
Curr Opin Virol; 2012 Feb; 2(1):50-9. PubMed ID: 22440966
[TBL] [Abstract][Full Text] [Related]
9. Discovery of natural mouse serum derived HIV-1 entry inhibitor(s).
Wei M; Chen Y; Xi J; Ru S; Ji M; Zhang D; Fang Q; Tang B
Acta Virol; 2016; 60(4):404-409. PubMed ID: 27928921
[TBL] [Abstract][Full Text] [Related]
10. A RhoA-derived peptide inhibits human immunodeficiency virus-1 entry in vitro.
Maselko M; Ward C; Pastey M
Curr HIV Res; 2011 Jan; 9(1):1-5. PubMed ID: 21198428
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, antiviral activity and resistance of a novel small molecule HIV-1 entry inhibitor.
Curreli F; Haque K; Xie L; Qiu Q; Xu J; Yong W; Tong X; Debnath AK
Bioorg Med Chem; 2015 Dec; 23(24):7618-28. PubMed ID: 26602829
[TBL] [Abstract][Full Text] [Related]
12. Antiviral activity of a Rac GEF inhibitor characterized with a sensitive HIV/SIV fusion assay.
Pontow S; Harmon B; Campbell N; Ratner L
Virology; 2007 Nov; 368(1):1-6. PubMed ID: 17640696
[TBL] [Abstract][Full Text] [Related]
13. A natural theaflavins preparation inhibits HIV-1 infection by targeting the entry step: potential applications for preventing HIV-1 infection.
Yang J; Li L; Tan S; Jin H; Qiu J; Mao Q; Li R; Xia C; Jiang ZH; Jiang S; Liu S
Fitoterapia; 2012 Mar; 83(2):348-55. PubMed ID: 22155187
[TBL] [Abstract][Full Text] [Related]
14. Antiviral propierties of 5,5'-dithiobis-2-nitrobenzoic acid and bacitracin against T-tropic human immunodeficiency virus type 1.
Lara HH; Ixtepan-Turrent L; Garza-Treviño EN; Flores-Teviño SM; Borkow G; Rodriguez-Padilla C
Virol J; 2011 Mar; 8():137. PubMed ID: 21435237
[TBL] [Abstract][Full Text] [Related]
15. A Lipopeptide HIV-1/2 Fusion Inhibitor with Highly Potent
Chong H; Xue J; Xiong S; Cong Z; Ding X; Zhu Y; Liu Z; Chen T; Feng Y; He L; Guo Y; Wei Q; Zhou Y; Qin C; He Y
J Virol; 2017 Jun; 91(11):. PubMed ID: 28356533
[TBL] [Abstract][Full Text] [Related]
16. HIV cell fusion assay: phenotypic screening tool for the identification of HIV entry inhibitors via CXCR4.
Smith EB; Ogert RA; Pechter D; Villafania A; Abbondanzo SJ; Lin K; Rivera-Gines A; Rebsch-Mastykarz C; Monsma FJ
J Biomol Screen; 2014 Jan; 19(1):108-18. PubMed ID: 23989454
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and evaluation of potential inhibitors of HIV gp120-CD4 interactions.
Boussard C; Klimkait T; Mahmood N; Pritchard M; Gilbert IH
Bioorg Med Chem Lett; 2004 May; 14(10):2673-6. PubMed ID: 15109676
[TBL] [Abstract][Full Text] [Related]
18. CD4-BFFI: a novel, bifunctional HIV-1 entry inhibitor with high and broad antiviral potency.
Jekle A; Chow E; Kopetzki E; Ji C; Yan MJ; Nguyen R; Sankuratri S; Cammack N; Heilek G
Antiviral Res; 2009 Sep; 83(3):257-66. PubMed ID: 19559732
[TBL] [Abstract][Full Text] [Related]
19. Amino acid derivatives of the (-) enantiomer of gossypol are effective fusion inhibitors of human immunodeficiency virus type 1.
An T; Ouyang W; Pan W; Guo D; Li J; Li L; Chen G; Yang J; Wu S; Tien P
Antiviral Res; 2012 Jun; 94(3):276-87. PubMed ID: 22426469
[TBL] [Abstract][Full Text] [Related]
20. The V1-V3 region of a brain-derived HIV-1 envelope glycoprotein determines macrophage tropism, low CD4 dependence, increased fusogenicity and altered sensitivity to entry inhibitors.
Rossi F; Querido B; Nimmagadda M; Cocklin S; Navas-Martín S; Martín-García J
Retrovirology; 2008 Oct; 5():89. PubMed ID: 18837996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
